MedTrace Logo

Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19

NCT04411667 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2021-06-25

Study results available
· View outcomes & findings →

Summary

The purpose of this research is to see if Intravenous Immunoglobulin (IVIG) can help reduce respiratory complications (respiratory failure and need for a ventilator) caused by coronavirus disease 2019 (COVID-19). The principal investigator has successfully utilized IVIG for patients infected with the influenza virus. The investigator wants to find out if IVIG is equally effective in COVID-19 infection patients, and if IVIG will give the immune system some help to clear the infection naturally.

Conditions

  • Sars-CoV2

Interventions

DRUG

Octagam

Standard of Care plus Octagam infusion for 3 days.

Sponsors & Collaborators

  • Octapharma

    collaborator INDUSTRY

  • George Sakoulas, MD

    lead OTHER

Principal Investigators

  • George Sakoulas, MD · Sharp HealthCare

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-28
Primary Completion
2020-06-23
Completion
2020-06-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04411667 on ClinicalTrials.gov